Recovery is a round-the-clock process.

Give patients a discreet, 24/7 tool to complement remote or in-office addiction therapy. reSET-O®, for opioid use disorder, is the only FDA-authorized digital treatment that’s proven to help patients stay in treatment longer.1,2 reSET®, for substance use disorder, is the first FDA-authorized treatment proven to increase abstinence and treatment retention.3,4 

Rethink addiction treatment.

Every year, millions of Americans struggling with addiction go untreated.5 Here’s how we recognize and break through the barriers to providing therapy.

Experience FDA-authorized prescription digital therapeutics.

Support outpatient therapy using clinically-proven, evidence-based techniques such as cognitive behavioral therapy, contingency management, and fluency training.2,4

See the process.

reSET-O and reSET are helping HCPs build on and monitor progress between appointments using at-a-glance insights into behavior patterns and patient-reported data that can make in-person sessions more productive and meaningful.2,4

Count on seamless support.

PearConnect™ is your innovative support center for reSET-O and reSET. From flexible prescribing options and proactive patient onboarding to benefits coverage and technical assistance, we’re here to help.

Interested in prescribing reSET-O or reSET?

reSET-O

Indications for Use:

reSET-O prescription digital therapeutic is a 12-week (84 day) software application intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment by providing cognitive behavioral therapy, as an adjunct to outpatient treatment that includes transmucosal buprenorphine and contingency management, for patients 18 years or older who are currently under the supervision of a clinician. reSET-O is indicated as a prescription-only digital therapeutic.

Important Safety Information for Clinicians:

Warnings: reSET-O is intended for patients whose primary language is English and who have access to an Android/iOS tablet or smartphone. reSET-O is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET-O to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET-O to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET-O is not intended to be used as a stand-alone therapy for Opioid Use Disorder (OUD). reSET-O does not replace care by a licensed medical practitioner. reSET-O does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

The long-term benefit of reSET-O has not been evaluated in studies lasting beyond 12 weeks (84 days) in the OUD population. The ability of reSET-O to prevent potential relapse after therapy discontinuation has not been studied.

Please see the Clinician Brief Summary Instructions for reSET-O.

reSET

Indications for Use:

reSET is intended to provide cognitive behavioral therapy, as an adjunct to a contingency management system, for patients 18 years of age and older, who are currently enrolled in outpatient treatment under the supervision of a clinician. reSET is indicated as a 12-week (90 day) prescription-only treatment for patients with substance use disorder (SUD), who are not currently on opioid replacement therapy, who do not abuse alcohol solely, or who do not abuse opioids as their primary substance of abuse.

It is intended to:

  • increase abstinence from a patient’s substances of abuse during treatment, and
  • increase retention in the outpatient treatment program.

 

Important Safety Information for Clinicians:

Warnings: reSET is intended for patients whose primary language is English and who have access to an Android/iOS tablet or smartphone. reSET is intended only for patients who own a smartphone and are familiar with use of smartphone apps (applications).

Clinicians should not use reSET to communicate with their patients about emergency medical issues. Patients should be clearly instructed not to use reSET to communicate to their clinician any urgent or emergent information. In case of an emergency, patients should dial 911 or go to the nearest emergency room.

reSET is not intended to be used as a stand-alone therapy for substance use disorder (SUD). reSET does not replace care by a licensed medical practitioner. reSET does not represent a substitution for a patient’s medication. Patients should continue to take their medications as directed by their healthcare provider.

The long-term benefit of treatment with reSET on abstinence has not been evaluated in studies lasting beyond 12 weeks (90 days) in the SUD population. The ability of reSET to prevent potential relapse after treatment discontinuation has not been studied.

Please see the Clinician Brief Summary Instructions for reSET.

 

References:

1. FDA clears mobile medical app to help those with opioid use disorder stay in recovery programs. News release. Silver Spring, MD: US Food and Drug Administration. December 10, 2018. Accessed May 18, 2020. https://www.fda.gov/news-events/press-announcements/fda-clears-mobile-medical-app-help-those-opioid-use-disorder-stay-recovery-programs

2. reSET-O Clinician directions for use. Pear Therapeutics, Inc. 2020.

3. FDA permits marketing of mobile medical application for substance use disorder. News release. Silver Spring, MD: US Food and Drug Administration. September 14, 2017. Accessed May 18, 2020. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-mobile-medical-application-substance-use-disorder

4. reSET Clinician directions for use. Pear Therapeutics, Inc. 2020.

5. Substance Abuse and Mental Health Services Administration. 2019. Key substance use and mental health Indicators In the United States: results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEPI9-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/

This information is intended for US healthcare professionals. Please confirm you are a healthcare professional to continue.